New Therapeutic Approaches and Insights for the Treatment and Understanding of Lung Disease

A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Respiratory Diseases".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 2788

Special Issue Editor


E-Mail Website
Guest Editor
Centre for Experimental Medicine, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
Interests: innate immune pesponse in the lung; acute and chronic disease; cystic fibrosis (CF); chronic obstructive pulmonary diseases (COPD); acute respiratory distress syndrome (ARDS)

Special Issue Information

Dear Colleagues,

Lung disease affects a large portion of the World’s population and is responsible for significant morbidity and mortality. Although a number of new treatments are now available, e.g., cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis lung disease, there remains a significant gap in the development of new treatments for other major lung diseases including chronic obstructive pulmonary disease. In this Special Issue, the authors outline some of the new developments in the pre-clinical arena which are leading to the generation of potentially exciting new treatments for lung disease. In addition, new mechanisms of disease are being uncovered in ground-breaking research that will herald the development of the next generation of new therapies to reduce the burden of lung disease worldwide.

Prof. Dr. Cliff Taggart
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cystic fibrosis
  • Chronic obstructive pulmonary disease
  • Acute lung disease
  • Lung repair
  • Inflammation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

6 pages, 226 KiB  
Review
Serum Biomarkers in a Radiological Pattern of Non-Fibrotic Hypersensitivity Pneumonitis: Implications for Mechanistic Difference and Differential Diagnosis
by Takayuki Takimoto and Yukihiro Nakamura
Diseases 2022, 10(3), 36; https://doi.org/10.3390/diseases10030036 - 27 Jun 2022
Viewed by 2158
Abstract
Hypersensitivity pneumonitis (HP) is a consequence of immune-mediated reactions caused by recurrent exposure to environmental agents. Recently, clinical practice guidelines for the diagnosis of HP were published and increased interest in HP. On the other hand, novel therapies have recently emerged for various [...] Read more.
Hypersensitivity pneumonitis (HP) is a consequence of immune-mediated reactions caused by recurrent exposure to environmental agents. Recently, clinical practice guidelines for the diagnosis of HP were published and increased interest in HP. On the other hand, novel therapies have recently emerged for various diseases, and the management of drug-related pneumonitis (DRP) has become increasingly important. Among DRP, the HP pattern (DRP-HP) shows small, poorly defined centrilobular nodules with or without widespread areas of ground-glass opacity or lobular areas of decreased attenuation and vascularity. A similar radiological pattern of non-fibrotic HP can be induced, irrespective of inhalation (non-fibrotic HP) or intravenous administration (DRP-HP). However, their difference has not been well described, although the distribution of lesions in the lungs was slightly different between these two conditions. In this review, we focus on serum biomarkers of lung epithelial cells in order to investigate the difference between DRP-HP and non-fibrotic HP (common-HP). Serum levels of Krebs von den Lungen 6 (KL-6) might be relatively lower (occasionally normal) in DRP-HP than in common-HP, implying a mechanistic difference. KL-6 could be useful in discriminating between DRP and non-fibrotic HP (common type). Full article
Back to TopTop